Nonalcoholic fatty liver disease and bariatric surgery

References

• Bellentani S, Saccoccio G, Masutti F et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med.132, 112–117 (2000).
   PubMed Web of Science ®Google Scholar
• Lam B, Younossi ZM. Novel treatment strategies for patients witn nonalcoholic fatty liver disease. Clin. Invest.1(2), 229–239 (2011).
   Google Scholar
• Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology37(4), 917–923 (2003).
   PubMed Web of Science ®Google Scholar
• Weiner RA. Surgical treatment of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Dig. Dis.28(1), 274–279 (2010).
   PubMed Web of Science ®Google Scholar
• Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin. Liver Dis.13(2), 249–266 (2009).
   PubMed Web of Science ®Google Scholar
• Sanyal AJ. NASH: a global health problem. Hepatol. Res.41(7), 670–674 (2011).
   PubMed Web of Science ®Google Scholar
• Blackburn GL, Hutter MM, Harvey AM et al. Expert panel on weight loss surgery: executive report update. Obesity (Silver Spring)17(5), 842–862 (2009).
   PubMed Web of Science ®Google Scholar
• Brunt EM. Pathology of nonalcoholic steatohepatitis. Hepatol. Res.33(2), 68–71 (2005).
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology41(6), 1313–1321 (2005).
   PubMed Web of Science ®Google Scholar
• Brunt EM, Kleiner DE, Wilson LA et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology53(3), 810–280 (2011).
   PubMed Web of Science ®Google Scholar
• Arun J, Jhala N, Lazenby AJ, Clements R, Abrams GA. Influence of liver biopsy heterogeneity and diagnosis of nonalcoholic steatohepatitis in subjects undergoing gastric bypass. Obes. Surg.17(2), 155–161 (2007).
   PubMedGoogle Scholar
• Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology128(7), 1898–1906 (2005).
   PubMed Web of Science ®Google Scholar
• Merriman RB, Ferrell LD, Patti MG et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology44(4), 874–880 (2006).
   PubMed Web of Science ®Google Scholar
• Ratziu V, Bugianesi E, Dixon J et al. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment. Pharmacol. Ther.26(6), 821–830 (2007).
   PubMed Web of Science ®Google Scholar
• Postic C, Girard J. The role of the lipogenic pathway in the development of hepatic steatosis. Diabetes Metab.34(6 Pt 2), 643–648 (2008).
   PubMed Web of Science ®Google Scholar
• Harmon RC, Tiniakos DG, Argo CK. Inflammation in nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol.5(2), 189–200 (2011).
   PubMed Web of Science ®Google Scholar
• Serviddio G, Bellanti F, Vendemiale G, Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Expert Rev. Gastroenterol. Hepatol.5(2), 233–244 (2011).
   PubMed Web of Science ®Google Scholar
• Tarantino G, Conca P, Riccio A et al. Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? J. Transl. Med.6, 72 (2008).
   PubMedGoogle Scholar
• Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver – the link between adipocytes and hepatocytes. Digestion83(1–2), 124–133 (2011).
   PubMed Web of Science ®Google Scholar
• Baranova A, Randhawa M, Jarrar M, Younossi ZM. Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: nonalcoholic fatty liver disease. Expert Rev. Mol. Diagn.7(2), 195–205 (2007).
   PubMed Web of Science ®Google Scholar
• Tataranni PA, Ortega E. A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on Type 2 diabetes? Diabetes54(4), 917–927 (2005).
   PubMed Web of Science ®Google Scholar
• Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology132(6), 2169–2180 (2007).
   PubMed Web of Science ®Google Scholar
• Verrijken A, Francque S, Mertens I et al. Visceral adipose tissue and inflammation correlate with elevated liver tests in a cohort of overweight and obese patients. Int. J. Obes. (Lond.)34(5), 899–907 (2010).
   PubMedGoogle Scholar
• Baranova A, Gowder SJ, Schlauch K et al. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes. Surg.16(9), 1118–1125 (2006).
   PubMed Web of Science ®Google Scholar
• Estep M, Armistead D, Hossain N et al. Differential expression of miRNAs in the visceral adipose tissue of patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther.32(3), 487–497 (2010).
   PubMed Web of Science ®Google Scholar
• Baranova A, Schlauch K, Elariny H et al. Gene expression patterns in hepatic tissue and visceral adipose tissue of patients with non-alcoholic fatty liver disease. Obes. Surg.17(8), 1111–1118 (2007).
   PubMedGoogle Scholar
• Stefan N, Kantartzis K, Machann J et al. Identification and characterization of metabolically benign obesity in humans. Arch. Intern. Med.168(15), 1609–1616 (2008).
   PubMed Web of Science ®Google Scholar
• Tarantino G, Colicchio P, Conca P et al. Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively? J. Inflamm. (Lond.)6, 6 (2009).
   PubMed Web of Science ®Google Scholar
• Huang MA, Greenson JK, Chao C et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am. J. Gastroenterol.100, 1072–1081 (2005).
   PubMed Web of Science ®Google Scholar
• Vilar Gomez E, Rodriguez De Miranda A, Gra Oramas B et al. Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther.30(10), 999–1009 (2009).
   PubMed Web of Science ®Google Scholar
• Ueno T, Sugawara H, Sujaku K et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J. Hepatol.27(1), 103–107 (1997).
   PubMed Web of Science ®Google Scholar
• Solga S, Alkhuraishe AR, Clark JM et al. Dietary composition and nonalcoholic fatty liver disease. Dig. Dis. Sci.49, 1578–1583 (2004).
   PubMed Web of Science ®Google Scholar
• Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ335(7631), 1194–1199 (2007).
   PubMed Web of Science ®Google Scholar
• Mallat A, Lotersztajn S. Endocannabinoids and their role in fatty liver disease. Dig. Dis.28(1), 261–266 (2010).
   PubMedGoogle Scholar
• Coletta DK, Bates SH, Jones RB, Bailey CJ. The sibutramine metabolite M2 improves muscle glucose uptake and reduces hepatic glucose output: preliminary data. Diab. Vasc. Dis. Res.3(3), 186–188 (2006).
   PubMedGoogle Scholar
• Aberle J, Freier A, Busch P et al. Treatment with sibutramine prior to Roux-en-Y gastric bypass leads to an improvement of metabolic parameters and to a reduction of liver size and operative time. Obes. Surg.19(11), 1504–1507 (2009).
   PubMedGoogle Scholar
• Florakis D, Diamanti-Kandarakis E, Katsikis I et al. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. Int. J. Obes. (Lond.)32(4), 692–699 (2008).
   PubMed Web of Science ®Google Scholar
• Assy N, Hussein O, Abassi Z. Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut56(3), 443–444 (2007).
   PubMed Web of Science ®Google Scholar
• Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial. Hepatology49(1), 80–86 (2009).
   PubMed Web of Science ®Google Scholar
• Wilson NS, Shah N, Manitpisitkul W et al. Liver failure requiring transplantation after orlistat use. Pharmacotherapy31(11), 1145 (2011).
   Google Scholar
• No authors listed. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development Conference Panel. Ann. Intern. Med.115(12), 956–961 (1991).
   PubMed Web of Science ®Google Scholar
• Glatt D, Sorenson T. Metabolic and bariatric surgery for obesity: a review. South Dakota Med.57–62 (2011).
   Google Scholar
• Mechanick JI, Kushner RF, Sugerman HJ et al. American Association of Clinical Endocriologists, the Obesity Society, and American Society for Metabolic and Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and non-surgical support of the bariatric surgery patient. Surg. Obes. Relat. Dis.4, S109–S184 (2008).
   PubMed Web of Science ®Google Scholar
• Ribeireiro T, Swain J, Sarr M et al. NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgery – a prospective analysis. Obes. Surg.21(3), 310–315 (2011).
   PubMedGoogle Scholar
• Zhao Y, Enciosa W. CT Bariatric Surgery Utilization and Outcomes in 1998 and 2004. Statistical Brief #23. Agency for Healthcare Research and Quality, MD, USA (2007).
   Google Scholar
• Padwal R, Klarenbach S, Wiebe N et al. Bariatric surgery: a systematic review of the clinical and economic evidence. J. Gen. Intern. Med.26(10), 1183–1194 (2011).
   PubMed Web of Science ®Google Scholar
• Sugerman HJ, Starkey JV, Birkenhauer R. A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters. Ann. Surg.205, 613–624 (1987).
   PubMed Web of Science ®Google Scholar
• Belachew M, Legrand M, Vincenti VV et al. Laparoscopic placement of adjustable silicone gastric band in the treatment of morbid obesity: how to do it. Obes. Surg.5, 66–70 (1995).
   PubMedGoogle Scholar
• Himpens J, Dapri G, Cadière GB. A prospective randomized study between laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results after 1 and 3 years. Obes. Surg.16, 1450–1456 (2006).
   PubMed Web of Science ®Google Scholar
• Halverson JD, Wise L, Wazna MF, Ballinger WF. Jejunoileal bypass for morbid obesity. A critical appraisal. Am. J. Med.64, 461–475 (1978).
   PubMed Web of Science ®Google Scholar
• Elder KA, Wolfe BM. Bariatric Surgery: a review of procedures and outcomes. Gastroenterology132, 2253–2271 (2007).
   PubMed Web of Science ®Google Scholar
• Mun EC, Blackburn GL, Mathews JB. Current status of medical and surgical therapy for obesity. Gastroenterology120, 669–681 (2001).
   PubMed Web of Science ®Google Scholar
• Prachand VN, Ward M, Alverdy JC. Duodenal switch provides superior resolution of metabolic comorbidities independent of weight loss in the super- obese (BMI> or= 50 kg/m2) compared with gastric bypass. J. Gastrointest. Surg.14, 211–220 (2010).
   PubMedGoogle Scholar
• Prachand VN, Davee RT, Alverdy JC. Duodenal switch provides superior weight loss in the super obese (BMI> or=50kg/m2) compared with gastric bypass. Ann. Surg.244, 611–619 (2006).
   PubMed Web of Science ®Google Scholar
• Grimm IS, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am. J. Gastroenterol.87, 775–779 (1992).
   PubMed Web of Science ®Google Scholar
• Friis R, Vaziri ND, Akbarpour F et al. Effect of rapid weight loss with supplemented fasting on liver tests. J. Clin. Gastroenterol.9(2), 204–207 (1987).
   PubMedGoogle Scholar
• Andersen T, Gluud C, Franzmann MB et al. Hepatic effects of dietary weight loss in morbidly obese subjects. J. Hepatol.12(2), 224–229 (1991).
   PubMed Web of Science ®Google Scholar
• Dixon JB, Bhathal PS, O’Brien PE. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement. Obes. Surg.16(10), 1278–1286 (2006).
   PubMed Web of Science ®Google Scholar
• Furuya CK Jr, de Oliveira CP, de Mello ES et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J. Gastroenterol. Hepatol.22(4), 510–514 (2007).
   PubMed Web of Science ®Google Scholar
• Mathurin P, Hollebecque A, Arnalsteen L et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology137, 532–540 (2009).
   PubMed Web of Science ®Google Scholar
• Bell LN, Temm CJ, Saxena R et al. Bariatric surgery-induced weight loss reduces hepatic lipid peroxidation levels and affects hepatic cytochrome P-450 protein content. Ann. Surg.251(6), 1041–1048 (2010).
   PubMed Web of Science ®Google Scholar
• Moschen AR, Molnar C, Wolf AM et al. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J. Hepatol.51(4), 765–777 (2009).
   PubMed Web of Science ®Google Scholar
• Cobb WS, Heniford BT, Burns JM et al. Cirrhosis is not a contra-indication to laparoscopic surgery. Surg. Endosc.19, 418–423 (2005).
   PubMed Web of Science ®Google Scholar
• Takata MC, Campos GM, Ciovica R et al. Laparoscopic bariatric surgery improves candidacy in morbidly obese patients awaiting transplantation. Surg. Obes. Relat. Dis.4, 159–165 (2008).
   PubMed Web of Science ®Google Scholar
• Dallal RM, Mattar SG, Lord JL et al. Results of laparoscopic gastric bypass in patients with cirrhosis. Obes. Surg.14, 47–53 (2004).
   PubMed Web of Science ®Google Scholar
• Mosko JD, Nguyen GC. Increased perioperative mortality following bariatric surgery among patients with cirrhosis. Clin. Gastroenterol. Hepatol.9(10), 897–901 (2011).
   PubMed Web of Science ®Google Scholar
• Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology39(6), 1647–1654 (2004).
   PubMed Web of Science ®Google Scholar
• Kral JG, Thung SN, Biron S et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery135(1), 48–58 (2004).
   PubMed Web of Science ®Google Scholar
• Clark JM, Alkhuraishi AR, Solga SF et al. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes. Res.13(7), 1180–1186 (2005).
   PubMedGoogle Scholar
• Mattar SG, Velcu LM, Rabinovitz M et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann. Surg.242(4), 610–617 (2005).
   PubMed Web of Science ®Google Scholar
• Barker KB, Palekar NA, Bowers SP et al. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery. Am. J. Gastroenterol.101(2), 368–373 (2006).
   PubMed Web of Science ®Google Scholar
• Csendes A, Smok G, Burgos AM. Histological findings in the liver before and after gastric bypass. Obes. Surg.16(5), 607–611 (2006).
   PubMed Web of Science ®Google Scholar
• de Almeida SR, Rocha PR, Sanches MD et al. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity. Obes. Surg.16(3), 270–278 (2006).
   PubMed Web of Science ®Google Scholar
• Klein S, Mittendorfer B, Eagon JC et al. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease. Gastroenterology130(6), 1564–1572 (2006).
   PubMed Web of Science ®Google Scholar
• Mathurin P, Gonzalez F, Kerdraon O et al. The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology130(6), 1617–1624 (2006).
   PubMed Web of Science ®Google Scholar